Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Apr 05, 2024

SELL
$3.85 - $28.47 $30,800 - $227,760
-8,000 Closed
0 $0
Q2 2020

Apr 05, 2024

BUY
$16.01 - $34.69 $128,080 - $277,520
8,000 New
8,000 $230 Million

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track E. Ohman J:Or Asset Management Ab Portfolio

Follow E. Ohman J:Or Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.